Revolutionizing Healthcare: Inquis Medical Secures $40 Million in Series B Funding Round

Inquis Medical, Inc., a pioneering clinical stage medical device company based in the heart of Silicon Valley, is excited to announce the successful completion of a $40 million funding round aimed at enhancing its groundbreaking efforts in the field of venous thromboembolic disease management. With a legacy rooted in decades of innovation and a commitment to creating physician-tested solutions, Inquis Medical has developed a cutting-edge, proprietary thrombectomy technology designed to deliver efficient single-pass thrombectomy procedures while minimizing blood loss. This latest round of funding will enable the company to accelerate the clinical development and market readiness of this next-generation device, which addresses a significant unmet need in the healthcare industry. By streamlining the thrombectomy process, Inquis Medical is poised to improve patient outcomes and reduce complications associated with venous thromboembolic diseases, such as deep vein thrombosis and pulmonary embolism. The support from our investors will not only assist in finalizing critical clinical trials but also bolster our efforts in expanding our research and development capabilities. As Inquis Medical continues on this innovative journey, we invite healthcare professionals, patients, and stakeholders to join us in transforming the future of thrombectomy care. For inquiries or further information, please contact us at info@inquismedical.com. Together, let's redefine the possibilities in medical intervention and improve lives across the globe.